

# Topical Ketamine:

## A REVIEW OF THE HISTORY, MECHANISMS, USES, SAFETY, AND FUTURE

 **Joseph Rabi, MD**

### REFERENCES

1. The American Academy of Pain Medicine. *American Academy of Pain Medicine Facts and Figures on Pain*. [AAPM Website.] Available at: [www.painmed.org/patientcenter/facts\\_on\\_pain.aspx](http://www.painmed.org/patientcenter/facts_on_pain.aspx). Accessed December 2015.
2. Committee on Advancing Pain Research, Care, and Education; Board on Health Sciences Policy; Institute of Medicine. *Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research*. Washington, DC: The National Academies or Press; 2011. [NAP Website.] Available at: [http://books.nap.edu/openbook.php?record\\_id=13172&page=1](http://books.nap.edu/openbook.php?record_id=13172&page=1). Accessed December 2015.
3. Stanos SP. Topical agents for the management of musculoskeletal pain. *J Pain Symptom Manage* 2007; 33(3): 342–355.
4. Payne R, Mathias SD, Pasta DJ et al. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl versus oral morphine. *J Clin Oncol* 1998; 16(4): 1588–1593.
5. Jarupanich T, Lamlertkittikul S, Chandeying V. Efficacy, safety and acceptability of a seven-day, transdermal estradiol patch for estrogen replacement therapy. *J Med Assoc Thai* 2003; 86(9): 836–845.
6. Archer DF, Cullins V, Creasy GW et al. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. *Contraception* 2004; 69(3): 189–195.
7. Brown D. Compounding pharmacies rise in popularity but bring questions about safety. *Washington Post*. [The Washington Post Website.] Oct 13 2012. Available at: [www.washingtonpost.com/national/health-science/compounding-pharmacies-rise-in-popularity-but-bring-questions-about-safety/2012/10/13/e87f8cc2-14a0-11e2-ba83-a7a396e6b2a7\\_story.html](http://www.washingtonpost.com/national/health-science/compounding-pharmacies-rise-in-popularity-but-bring-questions-about-safety/2012/10/13/e87f8cc2-14a0-11e2-ba83-a7a396e6b2a7_story.html). Accessed December 2015.
8. Harden RN. Ketamine analgesia: A call for better science. *Pain Med* 2012; 13(2): 145–147.
9. Miller KE, Hoffman EM, Sutharshan M et al. Glutamate pharmacology and metabolism in peripheral primary afferents: Physiological and pathophysiological mechanisms. *Pharmacol Ther* 2011; 130(3): 283–309.
10. Trist DG. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications. *Pharm Acta Helv* 2000; 74(2–3): 221–229.
11. Chizh BA, Headley PM. NMDA antagonists and neuropathic pain: Multiple drug targets and multiple uses. *Curr Pharm Des* 2005; 11(23): 2977–2994.
12. Coggeshall RE, Carlton SM. Receptor localization in the mammalian dorsal horn and primary afferent neurons. *Brain Res Rev* 1997; 24(1): 28–66.
13. Carlton SM, Hargett GL, Coggeshall RE. Localization and activation of glutamate receptors in unmyelinated axons of rat glabrous skin. *Neurosci Lett* 1995; 197(1): 25–28.
14. Coggeshall RE, Carlton SM. Ultrastructural analysis of NMDA, AMPA, and kainate receptors on unmyelinated and myelinated axons in the periphery. *J Comp Neurol* 1998; 391(1): 78–86.
15. Gupta A, Devi LA, Gomes I. Potentiation of  $\kappa$ -opioid receptor-mediated signaling by ketamine. *J Neurochem* 2011; 119(2): 294–302.
16. Moaddel R, Abdrakhmanova G, Kozak J et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in  $\alpha 7$  nicotinic acetylcholine receptors. *Eur J Pharmacol* 2013; 698(1–3): 228–234.
17. Murrrough JW. Ketamine as a novel antidepressant: From synapse to behavior. *Clin Pharmacol Ther* 2012; 91(2): 303–309.
18. Schnoebel R, Wolff M, Peters SC et al. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents. *Br J Pharmacol* 2005; 146(6): 826–833.
19. Kohrs R, Durieux ME. Ketamine: Teaching an old drug new tricks. *Anesth Analg* 1998; 87(5): 1186–1193.
20. Nishimura M, Sato K, Okada T et al. Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. *Anesthesiology* 1998; 88(3): 768–774.
21. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2) receptors-implications for models of schizophrenia. *Mol Psychiatry* 2002; 7(8): 837–844.
22. Kubota T, Hirota K, Yoshida H et al. Inhibitory effect of clonidine on ketamine-induced norepinephrine release from medial prefrontal cortex in rats. *Br J Anesth* 1999; 83(6): 945–947.

23. Lindefors N, Barati S, O'Connor WT. Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex. *Brain Res* 1997; 759(2): 205–212.
24. Seeman P, Ko F, Tallerico T. Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. *Mol Psychiatry* 2005; 10(9): 877–883.
25. Romero TR, Galdino GS, Silva GC et al. Ketamine activates the L-arginine/Nitric oxide/cyclic guanosine monophosphate pathway to induce peripheral antinociception in rats. *Anesth Analg* 2011; 113(5): 1254–1259.
26. Liu FL, Chen TL, Chen RM. Mechanisms of ketamine-induced immunosuppression. *Acta Anaesthesiol Taiwan* 2012; 50(4): 172–177.
27. Professional Compounding Centers of America. *A Validated Transdermal Vehicle with Superior Results over the Competition*. [PCCA Website.] Available at: [http://beta.pccarx.com/pdf\\_files/98591\\_Lipoderm30-3338\\_PRACT.pdf](http://beta.pccarx.com/pdf_files/98591_Lipoderm30-3338_PRACT.pdf). 2013. Accessed December 2015.
28. Barros GA, Miot HA, Braz AM et al. Topical (S)-ketamine for pain management of postherpetic neuralgia. *An Bras Dermatol* 2012; 87(3): 504–505.
29. Quan D, Wellish M, Gilden DH. Topical ketamine treatment of postherpetic neuralgia. *Neurology* 2003; 60(8): 1391–1392.
30. Lynch ME, Clark AJ, Sawynok J et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: An open-label study. *J Pain* 2005; 6(10): 644–649.
31. Lynch ME, Clark AJ, Sawynok J et al. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: A randomized, double-blind, placebo-controlled trial. *Anesthesiology* 2005; 103(1): 140–146.
32. Lockhart E. Topical combination of amitriptyline and ketamine for post herpetic neuralgia. *J Pain* 2004; 5: 82.
33. Gammaitoni A, Gallagher RM, Welz-Bosna M. Topical ketamine gel: Possible role in treating neuropathic pain. *Pain Med* 2000; 1(1): 97–100.
34. ClinicalTrials.gov. A study of the efficacy and safety of amitriptyline/ketamine topical cream in patients with diabetic peripheral neuropathy. 2008: NCT00476151. [ClinicalTrials.gov Website.] Available at: <http://clinicaltrials.gov/show/nct00476151>. Accessed December 2015.
35. Lynch ME, Clark AJ, Sawynok J et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: An open-label study. *J Pain* 2005; 6(10): 644–649.
36. Mahoney JM, Vardaxis V, Moore JL et al. Topical ketamine cream in the treatment of painful diabetic neuropathy: A randomized, placebo-controlled, double-blind initial study. *JAM Podiatr Med Assoc* 2012; 102(3): 178–183.
37. Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. *Pain* 2009; 146(1–2): 18–25.
38. Ushida T, Tani T, Kanbara T et al. Analgesic effects of ketamine ointment in patients with complex regional pain syndrome type 1. *Reg Anesth Pain Med* 2002; 27(5): 524–528.
39. Crowley KL, Flores JA, Hughes CN et al. Clinical application of ketamine ointment in the treatment of sympathetically maintained pain. *IJPC* 1998; 2(2): 122–127.
40. Keppel Hesselink JM, Kopsky DJ. Treatment of chronic regional pain syndrome type 1 with palmitoylethanolamide and topical ketamine cream: Modulation of nonneuronal cells. *J Pain Res* 2013; 6: 239–245.
41. Kopsky DJ, Keppel Hesselink JM. Multimodal stepped care approach involving topical analgesics for severe intractable neuropathic pain in CRPS type 1: A case report. *Case Rep Med* 2011: 319750.
42. Barton DL, Wos EJ, Qin R et al. A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. *Support Care Cancer* 2011; 19(6): 833–841.
43. Gewandter JS, Mohile SG, Heckler CE et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): A University of Rochester CCOP study of 462 cancer survivors. *Support Care Cancer* 2014; 22(7): 1807–1814.
44. Prommer EE. Topical analgesic combinations for bortezomib neuropathy. *J Pain Symptom Manage* 2009; 37(3): e3–e5.
45. Hershman DL, Lacchetti C, Dworkin RH et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. *J Clin Oncol* 2014; 32(18): 1941–1967.
46. Poterucha TJ, Murphy SL, Rho RH et al. Topical amitriptyline-ketamine for treatment of rectal, genital, and perineal pain and discomfort. *Pain Physician* 2012; 15(6): 485–488.
47. Hesselink JM, Kopsky DJ. Intractable neuropathic pain due to ulnar nerve entrapment treated with cannabis and ketamine 10%. *J Clin Anesth* 2012; 24(1): 78–79.
48. U.S. Department of Health & Human Services. National Institutes of Health. National Center for Advancing Translational Sciences. Genetic and Rare Disease Information Center. Maakaron JE, Taha A. Erythromelalgia. *Medscape Reference*. [National Institutes of Health Website.] March 2014. Available at: <http://emedicine.medscape.com/article/200071-overview>. Accessed December 2015.
49. Poterucha TJ, Weiss WT, Warndahl RA et al. Topical amitriptyline combined with ketamine for the treatment of erythromelalgia: A retrospective study of 36 patients at Mayo Clinic. *J Drugs Dermatol* 2013; 12(3): 308–310.
50. Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: A new treatment option? *Arch Dermatol* 2006; 142(3): 283–286.
51. Tam E, Furlan AD. Transdermal lidocaine and ketamine for neuropathic pain: A study of effectiveness and tolerability. *Open Neurol J* 2012; 6: 58–64.

52. Poterucha TJ, Murphy SL, Sandroni P et al. Topical amitriptyline combined with topical ketamine for the management of recalcitrant localized pruritus: A retrospective pilot study. *JAM Acad Dermatol* 2013; 69(2): 320–321.
53. Poterucha TJ, Murphy SL, David MD et al. Topical amitriptyline-ketamine for the treatment of brachioradial pruritis. *JAMA Dermatol* 2013; 149(2): 148–150.
54. Mirzoyev SA, Davis MD. Brachioradial pruritus: Mayo Clinic experience over the past decade. *Br J Dermatol* 2013; 169(5): 1007–1015.
55. Uzaraga I, Gerbis B, Holwerda E et al. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: A pilot study. *Support Care Cancer* 2012; 20(7): 1515–1524.
56. Tekelioglu UY, Apuhan T, Akkaya A et al. Comparison of topical tramadol and ketamine in pain treatment after tonsillectomy. *Paediatr Anesth* 2013; 23(6): 496–501.
57. Canbay O, Celebi N, Uzun S et al. Topical ketamine and morphine for post-tonsillectomy pain. *Eur J Anesthesiol* 2008; 25(4): 287–292.
58. Sullivan RW, Ryzewski M, Holland MG et al. Compounded ointment results in severe toxicity in a pediatric patient. *Pediatr Emerg Care* 2013; 29(11): 1220–1222.
59. Morley-Forster PK, Manikandan R, Railton C et al. Uptake of topical 10% ketamine gel over 7 days: A pilot study. Available at: <http://ar.kromamarketing.com/wp-content/uploads/2013/02/Uptake-of-Ketamine.pdf>. Accessed December 2015.
60. Carlton SM, Coggeshall RE. Inflammation-induced changes in peripheral glutamate receptor populations. *Brain Res* 1999; 820(1–2): 63–70.
61. Alfredson H, Forsgren S, Thorsen K et al. In vivo microdialysis and immunohistochemical analyses of tendon tissue demonstrated high amounts of free glutamate and glutamate NMDAR1 receptors, but no signs of inflammation, in Jumper's knee. *J Orthop Res* 2001; 19(5): 881–886.

*Address correspondence to Joseph Rabi, University of Chicago/Schwab Rehabilitation Hospital, 1401 South California Avenue, Chicago, IL 60608. E-mail: jrabi1@gmail.com*